The people bringing modern medicine to pets.

Elizabeth is a translational scientist with deep oncology credentials: PhD in Cancer Biology from the Institute of Cancer Research, London; postdoctoral and Assistant Professor positions at the University of Miami Miller School of Medicine focused on breast cancer; 60+ publications in leading journals.

Elizabeth co-founded and led Science Exchange as CEO from 2011 through its acquisition in 2024, building the R&D orchestration platform used by BMS, AbbVie, Gilead, Astellas, and other top pharmaceutical companies. She has been recognized by Goldman Sachs (100 Most Intriguing Entrepreneurs), Nature (Ten People That Mattered in 2012), Wired (50 Women Who Are Changing The World), and as a Scrip Awards Finalist for Executive of the Year.

Dan is an operations and finance leader with deep experience in technology, finance, biotech, and startups. He holds an MBA from MIT Sloan, an MSc in Economics from the University of London, and a BCom (Hons) in Economics and an LLB in Law from the University of Otago.

Dan co-founded Science Exchange with Elizabeth and built the operating model that grew it into the outsourced R&D infrastructure used by the world’s largest pharmaceutical companies, through its acquisition in 2024.

Stacy is a chemistry, manufacturing and controls leader with deep expertise across animal health and biotech. She was previously VP of CMC at Loyal, with earlier roles at Zoetis, Bayer Animal Health, Elanco and Sage Therapeutics. She has contributed to 12 FDA approvals and seven commercial products. She holds a PhD in Pharmaceutics from the University of Iowa.

Karen has worked in the Animal Health industry for 38 years, with > 25 years at Pfizer Animal Health & Zoetis, followed by leadership roles at Parnell, Kindred Biosciences and Loyal. She has broad experience including project and portfolio strategy and delivery and FDA CVM regulatory strategy and submissions. She was involved in development of multiple products including Apoquel, Cytopoint, the Canine Parvovirus Monoclonal Antibody and Solensia. After developing the regulatory path to market for Loyal she moved into a consulting role focused on helping start-up companies gain FDA CVM approval for veterinary products.

Mark has 20+ years of experience at large animal health pharmaceutical companies, including Zoetis, Novartis Animal Health and Pfizer Animal Health.

He has 28 years in regulatory affairs, including new product submissions, post-approval maintenance, and global registration support. His work spans a variety of product types, including sterile and non-sterile formulations. He also has 11 years of experience in manufacturing operations and 9 years in formulation R&D.

Tiffany has a decade of experience in analytical chemistry, with earlier roles at Merck. She is skilled in developing analytical methods and specifications for animal health products. Her expertise spans both physical and chemical methods, including HPLC/GC and MS, with a focus on impurity analysis and quality control. She also has extensive experience in CDMO troubleshooting and oversight.

James is a partner at DLA Piper and a life sciences corporate and transactions attorney with extensive experience counseling biotechnology and pharmaceutical companies on licensing, collaboration, R&D, manufacturing and supply, commercialization, and other strategic commercial arrangements. He holds a JD from Temple University School of Law.

James advises Familiar Therapeutics on its IP and commercial transactions that support the company's portfolio of products.

Pierre is a partner in DLA Piper's Philadelphia office and a registered patent attorney focused on life sciences. He advises on patent strategy, preparation and prosecution, due diligence and licensing, and has served as IP counsel on two biotech IPOs. He holds a PhD in pharmacology from the University of Pittsburgh and a JD from Duquesne University.